Citation: Akl. Banes et Sw. Watts, Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1B) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat, HYPERTENSIO, 38(4), 2001, pp. 891-895
Citation: Sw. Watts et al., Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors, J CARDIO PH, 38(4), 2001, pp. 539-551
Citation: Cm. Mckune et Sw. Watts, Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling, J PHARM EXP, 297(1), 2001, pp. 88-95
Authors:
Melis, A
Watts, SW
Florian, J
Klarr, S
Webb, RC
Citation: A. Melis et al., Insulin-like growth factor inhibits vascular contraction to 5-hydroxytryptamine: Involvement of tyrosine phosphatase, GEN PH-VASC, 34(2), 2000, pp. 137-145
Citation: Sw. Watts, 5-hydroxytryptamine-induced potentiation of endothelin-1-and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent, HYPERTENSIO, 35(1), 2000, pp. 244-248
Authors:
Watts, SW
Fink, GD
Silver, PJ
Cushing, DJ
Citation: Sw. Watts et al., Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors, J CARDIO PH, 35(1), 2000, pp. 29-36
Citation: Sw. Watts et Gd. Fink, 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats, AM J P-HEAR, 45(3), 1999, pp. H944-H952
Citation: Ja. Florian et Sw. Watts, Epidermal growth factor: a potent vasoconstrictor in experimental hypertension, AM J P-HEAR, 45(3), 1999, pp. H976-H983
Citation: Sw. Watts et B. Harris, Is functional upregulation of the 5-HT2B receptor in deoxycorticosterone acetate salt-treated rats blood pressure dependent?, GEN PHARM, 33(6), 1999, pp. 439-447
Citation: A. Banes et al., Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle, J PHARM EXP, 291(3), 1999, pp. 1179-1187